Q BioMed, Inc. operates as a biomedical acceleration and development company. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2014-11-17. The firm is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. The Company’s pipeline products include Strontium89, QBM-001, UTTROSIDE-B, and MAN 01. Strontium89 treats pain from bone metastases caused by multiple primary tumors. Strontium Chloride Sr-89 Injection, USP is indicated for the relief of bone pain in patients with painful skeletal metastases. QBM-001 is designed to alleviate the condition and allow toddlers to actively develop language and speech and avoid life-long speech and intellectual disabilities caused from being non-verbal. UTTROSIDE-B is a potential chemotherapeutic for liver cancer. MAN-01 is for the treatment of primary open-angle glaucoma, wherein it is developing a small molecule in the form of an easy to administer eye drop to reduce intra-ocular eye pressure (IOP), a key risk factor in the progression of glaucoma.
